A good antisense molecule is hard to find

Antisense molecules and ribozymes capture the imagination with their promise of rational drug design and exquisite specificity. However, they are far more difficult to produce than was originally anticipated, and their ability to eliminate the function of a single gene has never been proven. Furthermore, a wide variety of unexpected non-antisense effects have come to light. Although some of these side effects will almost certainly have clinical value, they make it hard to produce drugs that act primarily through true antisense mechanisms and complicate the use of antisense compounds as research reagents. To minimize unwanted non-antisense effects, investigators are searching for antisense compounds and ribozymes whose target sites are particularly vulnerable to attack. This is a challenging quest.

[1]  M. J. Martin,et al.  Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA , 1996, Antimicrobial agents and chemotherapy.

[2]  T. Gura.  Antisense Has Growing Pains , 1995, Science.

[3]  T. Tuschl,et al.  RNA cleavage by small catalytic RNAs. , 1995, Current opinion in structural biology.

[4]  Y. Cheng,et al.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.

[5]  B. Froehler,et al.  Potent and selective inhibition of gene expression by an antisense heptanucleotide , 1996, Nature Biotechnology.

[6]  R. E. Lockard,et al.  Secondary structure model for mouse beta Maj globin mRNA derived from enzymatic digestion data, comparative sequence and computer analysis. , 1986, Nucleic acids research.

[7]  A. Branch.  A Hitchhiker's guide to antisense and nonantisense biochemical pathways , 1996, Hepatology.

[8]  D. Spiller,et al.  Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. , 1995, Nucleic acids research.

[9]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[10]  C. Stein.  Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. , 1996, Trends in biotechnology.

[11]  R. Pictet,et al.  Can hammerhead ribozymes be efficient tools to inactivate gene function? , 1994, Nucleic acids research.

[12]  R. Symons,et al.  Plant pathogenic RNAs and RNA catalysis. , 1997, Nucleic acids research.

[13]  J. Burke.  Clearing the way for ribozymes , 1997, Nature Biotechnology.

[14]  W. Gerlach,et al.  Simple RNA enzymes with new and highly specific endoribonuclease activities , 1988, Nature.

[15]  S. Agrawal,et al.  In vivo studies with antisense oligonucleotides. , 1997, Trends in pharmacological sciences.

[16]  Robert A. Mueller,et al.  Principles of pharmacology : basic concepts and clinical applications , 1995 .

[17]  E. Southern,et al.  Selecting effective antisense reagents on combinatorial oligonucleotide arrays , 1997, Nature Biotechnology.

[18]  Steven E. Rokita,et al.  Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design , 1997, Nature Biotechnology.

[19]  O. Uhlenbeck,et al.  Specificity of hammerhead ribozyme cleavage. , 1996, The EMBO journal.

[20]  M. Blumenfeld,et al.  BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. , 1995, Blood.

[21]  A. Krieg,et al.  Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. , 1996, Antisense & nucleic acid drug development.

[22]  N G Anderson,et al.  Twenty years of two‐dimensional electrophoresis: Past, present and future , 1996, Electrophoresis.

[23]  C. Stein,et al.  Does antisense exist? , 1995, Nature Medicine.

[24]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[25]  A. Colman,et al.  Antisense oligodeoxyribonucleotide-directed cleavage of maternal mRNA in Xenopus oocytes and embryos. , 1988, Gene.

[26]  S. Crooke.  Proof of mechanism of antisense drugs. , 1996, Antisense & nucleic acid drug development.

[27]  F. Eckstein,et al.  The structure, function and application of the hammerhead ribozyme. , 1997, European journal of biochemistry.

[28]  R. Christoffersen.  Translating genomics information into therapeutics: A key role for oligonucleotides , 1997, Nature Biotechnology.

[29]  W Roush,et al.  Antisense Aims for a Renaissance , 1997, Science.

[30]  C. F. Bennett,et al.  Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.

[31]  R. Wagner,et al.  In pursuit of antisense. , 1996, Nature.

[32]  Doriano Fabbro,et al.  Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.

[33]  R. Cedergren,et al.  Efficient hammerhead ribozyme and antisense RNA targeting in a slow ribosome Escherichia colimutant , 1997, Nature Biotechnology.

[34]  Helen Donis-Keller,et al.  Site specific enzymatic cleavage of RNA , 1979, Nucleic Acids Res..

[35]  P. Martiat,et al.  Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. , 1997, Blood.